Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Markus Hoffmann and Stefan Pöhlmann.
Markus Hoffmann
Connection Strength
13.728
Stefan Pöhlmann
  1. How SARS-CoV-2 makes the cut. Nat Microbiol. 2021 07; 6(7):828-829.
    View in: PubMed
    Score: 0.954
  2. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021 07 20; 36(3):109415.
    View in: PubMed
    Score: 0.953
  3. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Rep. 2021 04 20; 35(3):109017.
    View in: PubMed
    Score: 0.938
  4. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021 04 29; 184(9):2384-2393.e12.
    View in: PubMed
    Score: 0.935
  5. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021 Mar; 65:103255.
    View in: PubMed
    Score: 0.933
  6. Dalbavancin: novel candidate for COVID-19 treatment. Cell Res. 2021 03; 31(3):243-244.
    View in: PubMed
    Score: 0.932
  7. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020 09; 585(7826):588-590.
    View in: PubMed
    Score: 0.894
  8. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother. 2020 05 21; 64(6).
    View in: PubMed
    Score: 0.883
  9. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 2020 05 21; 78(4):779-784.e5.
    View in: PubMed
    Score: 0.880
  10. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 04 16; 181(2):271-280.e8.
    View in: PubMed
    Score: 0.870
  11. Disease Manifestation and Viral Sequences in a Bonobo More Than 30 Years after Papillomavirus Infection. Pathogens. 2019 Jan 26; 8(1).
    View in: PubMed
    Score: 0.806
  12. Cell Entry of Influenza A Viruses: Sweet Talk between HA and CaV1.2. Cell Host Microbe. 2018 06 13; 23(6):697-699.
    View in: PubMed
    Score: 0.772
  13. A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry. J Virol. 2017 05 01; 91(9).
    View in: PubMed
    Score: 0.712
  14. Mutation D614G increases SARS-CoV-2 transmission. Signal Transduct Target Ther. 2021 03 01; 6(1):101.
    View in: PubMed
    Score: 0.233
  15. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 2020; 9(1):155-168.
    View in: PubMed
    Score: 0.216
  16. Calu-3 cells are largely resistant to entry driven by filovirus glycoproteins and the entry defect can be rescued by directed expression of DC-SIGN or cathepsin L. Virology. 2019 06; 532:22-29.
    View in: PubMed
    Score: 0.204
  17. Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization. J Virol. 2019 01 15; 93(2).
    View in: PubMed
    Score: 0.201
  18. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Sci Rep. 2018 11 09; 8(1):16597.
    View in: PubMed
    Score: 0.199
  19. TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. J Biol Chem. 2018 09 07; 293(36):13863-13873.
    View in: PubMed
    Score: 0.194
  20. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism. J Virol. 2018 07 01; 92(13).
    View in: PubMed
    Score: 0.193
  21. The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells. PLoS One. 2017; 12(12):e0189073.
    View in: PubMed
    Score: 0.186
  22. Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2. PLoS One. 2017; 12(6):e0179177.
    View in: PubMed
    Score: 0.180
  23. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol. 2021 10; 18(10):2455-2456.
    View in: PubMed
    Score: 0.060
  24. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 09; 27(9):1525-1529.
    View in: PubMed
    Score: 0.060
  25. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Med. 2021 07; 18(7):e1003656.
    View in: PubMed
    Score: 0.060
  26. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. PLoS Pathog. 2021 04; 17(4):e1009500.
    View in: PubMed
    Score: 0.059
  27. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. Nat Commun. 2021 03 19; 12(1):1726.
    View in: PubMed
    Score: 0.058
  28. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol. 2021 04; 18(4):936-944.
    View in: PubMed
    Score: 0.057
  29. LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat Microbiol. 2020 11; 5(11):1330-1339.
    View in: PubMed
    Score: 0.056
  30. Release of Immunomodulatory Ebola Virus Glycoprotein-Containing Microvesicles Is Suppressed by Tetherin in a Species-Specific Manner. Cell Rep. 2019 02 12; 26(7):1841-1853.e6.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.